{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:47:48Z","timestamp":1776930468928,"version":"3.51.2"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100003559","name":"Aesthetic Surgery Education and Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>CD30 lymphocyte activation antigen and phosphorylated STAT3 (pSTAT3) are consistent markers of tumor cells in breast implant\u2013associated anaplastic large cell lymphoma (BIA-ALCL). We present a case of BIA-ALCL in a breast implant capsule containing clustered tumor cells expressing CD30, pSTAT3, pSTAT6, interleukin 9, and granzyme B tumor cell biomarkers. Remarkably, the contralateral breast contained many scattered large, atypical CD30+ cells surrounded by inflammatory cells, raising a suspicion of bilateral BIA-ALCL, known to occur in some patients. To clarify the diagnosis, immunohistochemistry and multilabel immunofluorescence were performed. Unlike the tumor cells, the atypical CD30+ cells of the contralateral breast lacked pSTAT3, pSTAT6, interleukin 9, and granzyme B, eliminating a diagnosis of bilateral BIA-ALCL. This case highlights the importance of interpreting CD30 staining in the context of other tumor cell biomarkers and histopathology to avoid an incorrect diagnosis of BIA-ALCL. We believe the findings also suggest the possibility of CD30 expression as an early event in the multistep pathogenesis of BIA-ALCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Level of Evidence: 5<\/jats:title><jats:p\/><\/jats:sec>","DOI":"10.1093\/asj\/sjab215","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T13:17:18Z","timestamp":1620134238000},"page":"NP125-NP129","source":"Crossref","is-referenced-by-count":6,"title":["Nonmalignant CD30+ Cells in Contralateral Peri-Implant Capsule of Patient With BIA-ALCL: A Premalignant Step?"],"prefix":"10.1093","volume":"42","author":[{"given":"Marshall E","family":"Kadin","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Brown University Alpert Medical School , Providence, RI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Xu","sequence":"additional","affiliation":[{"name":"Rhode Island Hospital , Providence, RI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M","family":"Hunsicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brown University Alpert Medical School , Providence, RI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"2022112410193194000_CIT0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1096\/fasebj.9.1.7821763","article-title":"Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines","volume":"9","author":"Del Prete","year":"1995","journal-title":"FASEB J."},{"key":"2022112410193194000_CIT0002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J Clin Oncol."},{"key":"2022112410193194000_CIT0003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/asj\/sjw259","article-title":"NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma","volume":"37","author":"Clemens","year":"2017","journal-title":"Aesthet Surg J."},{"key":"2022112410193194000_CIT0004","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.19.02778","article-title":"Best practices guideline for the pathologic diagnosis of breast implant-associated anaplastic large-cell lymphoma","volume":"38","author":"Jaffe","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022112410193194000_CIT0005","doi-asserted-by":"crossref","first-page":"e0181097","DOI":"10.1371\/journal.pone.0181097","article-title":"Cytological diagnostic features of late breast implant seromas: from reactive to anaplastic large cell lymphoma","volume":"12","author":"Di Napoli","year":"2017","journal-title":"PLoS One."},{"key":"2022112410193194000_CIT0006","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/asj\/sjw286","article-title":"CD30+ cells in late seroma may not be diagnostic of BIA-ALCL","volume":"37","author":"Kadin","year":"2017","journal-title":"Aesthet Surg J."},{"key":"2022112410193194000_CIT0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjps.2020.10.064","article-title":"UK guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare Products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)","volume":"74","author":"Turton","year":"2021","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"2022112410193194000_CIT0008","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clbc.2013.08.009","article-title":"Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules","volume":"13","author":"Bautista-Quach","year":"2013","journal-title":"Clin Breast Cancer."},{"key":"2022112410193194000_CIT0009","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","article-title":"Genetic subtyping of breast implant-associated anaplastic large cell lymphoma","volume":"132","author":"Oishi","year":"2018","journal-title":"Blood."},{"key":"2022112410193194000_CIT0010","doi-asserted-by":"crossref","first-page":"36126","DOI":"10.18632\/oncotarget.26308","article-title":"Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma","volume":"9","author":"Blombery","year":"2018","journal-title":"Oncotarget."},{"key":"2022112410193194000_CIT0011","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.3324\/haematol.2016.146118","article-title":"Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma","volume":"101","author":"Blombery","year":"2016","journal-title":"Haematologica."},{"key":"2022112410193194000_CIT0012","article-title":"Cytokine receptor signaling is required for the survival of ALK\u2013 anaplastic large cell lymphoma, even in the presence of JAK1\/STAT3 mutations","author":"Chen","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2022112410193194000_CIT0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2018.04.007","article-title":"IL-13 is produced by tumor cells in breast implant associated anaplastic large cell lymphoma: implications for pathogenesis","author":"Kadin","year":"2018","journal-title":"Hum Pathol."},{"key":"2022112410193194000_CIT0014","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/asj\/sjz243","article-title":"Comparative analysis of cytokines of tumor cell lines, malignant and benign effusions around breast implants","volume":"40","author":"Kadin","year":"2020","journal-title":"Aesthet Surg J."},{"key":"2022112410193194000_CIT0015","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-020-02778-3","article-title":"IL-10, IL-13, eotaxin and IL-10\/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas","author":"Di Napoli","year":"2021","journal-title":"Cancer Immunol Immunother."},{"key":"2022112410193194000_CIT0016","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjaa302","article-title":"Granzyme B is a biomarker for suspicion of malignant seromas around breast implants","author":"Kadin","year":"2021","journal-title":"Aesthet Surg J."},{"key":"2022112410193194000_CIT0017","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/asj\/sjy327","article-title":"Validation of a CD30 enzyme-linked immunosorbant assay for the rapid detection of breast implant-associated anaplastic large cell lymphoma","volume":"40","author":"Hanson","year":"2020","journal-title":"Aesthet Surg J."},{"key":"2022112410193194000_CIT0018","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/his.13932","article-title":"Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management","volume":"75","author":"Jones","year":"2019","journal-title":"Histopathology."},{"key":"2022112410193194000_CIT0019","doi-asserted-by":"crossref","first-page":"30e","DOI":"10.1097\/PRS.0000000000006390","article-title":"Does breast implant-associated ALCL begin as a lymphoproliferative disorder?","volume":"145","author":"Kadin","year":"2020","journal-title":"Plast Reconstr Surg"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjab215\/38756063\/sjab215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/42\/2\/NP125\/47252692\/sjab215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/42\/2\/NP125\/47252692\/sjab215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T09:35:21Z","timestamp":1672047321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/42\/2\/NP125\/6263813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,5,4]]},"published-print":{"date-parts":[[2022,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjab215","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,5,4]]}}}